Racial disparities in pediatric cancer hospitalizations in the United States

Tugce Kutuk1, Raj Singh2, Vedat Yildiz3

  • 1Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, United States.

Cancer Epidemiology
|June 5, 2026
PubMed

Insights

Racial and socioeconomic disparities increase inpatient mortality for pediatric cancer patients in the U.S. Targeted strategies are needed to reduce inequities in pediatric cancer care and improve healthcare access for all children.

Area of Science:

  • Pediatric oncology
  • Health disparities research
  • Healthcare access and quality

Background:

  • Pediatric cancer patients face significant healthcare challenges.
  • Racial and socioeconomic factors may influence outcomes in pediatric cancer care.
  • Understanding disparities is crucial for improving treatment and survival rates.

Purpose of the Study:

  • To examine racial differences in pediatric cancer hospitalizations in the U.S.
  • To identify factors linked to inpatient mortality and non-routine discharge among these patients.
  • To highlight the need for equitable healthcare access and targeted interventions.

Main Methods:

  • Retrospective analysis of the Kids' Inpatient Database (KID) from 2006-2012.
  • Inclusion of patients aged 20 years or younger with a cancer diagnosis.
  • Multivariable logistic regression to analyze predictors of inpatient mortality, controlling for demographic, socioeconomic, and clinical variables.

Main Results:

  • Non-White pediatric cancer patients were more likely to be hospitalized in large metropolitan areas and have Medicaid insurance compared to White patients.
  • Inpatient mortality was higher in non-White pediatric cancer patients (1.5%) versus White patients (0.9%).
  • Black race, Native American/Other race, self-pay insurance, and lower income quartile were independently associated with increased odds of inpatient mortality.

Conclusions:

  • Significant racial and socioeconomic disparities exist in pediatric cancer-related hospitalizations and inpatient mortality in the U.S.
  • These disparities highlight critical inequities in pediatric cancer care and healthcare access.
  • Targeted strategies are essential to mitigate these disparities and ensure equitable outcomes for all children with cancer.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...